M
MoonLake Immunotherapeutics (MLTX)
NCM – Real Time Price. Currency in USD
18.19
-0.65 (-3.45%)
At close: May 12, 2026, 4:00 PM EDT
17.87
-0.32 (-1.76%)
Pre-market: May 13, 2026, 5:17 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
18.19
-0.65 (-3.45%)
At close: May 12, 2026, 4:00 PM EDT
17.87
-0.32 (-1.76%)
Pre-market: May 13, 2026, 5:17 AM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Company's cash reserves $334.5M significantly exceed its total debt $75.7M, ensuring strong financial flexibility
Total current assets $421.7M exceed Total current liabilities $45.5M, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-32.7x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$58.8M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 9.27 | 6.05 | 10 | |
| Quick ratio | 9.27 | 5.63 | 10 | |
| Debt to Equity | 0.25 | 0.30 | 8.0 | |
| Debt to Assets | 0.18 | 1.04 | 8.0 | |
| Interest coverage | -32.71 | -16.91 | 1.0 | |
| Weighted average score | 7.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -12K | -13K | -1M | -3M | -3M |
| Operating Income | -65M | -54M | -143M | -245M | -245M |
| Net Income | -50M | -36M | -119M | -227M | -227M |
| EBITDA | -65M | -54M | -142M | -242M | -242M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -41.55 | 1.0 |
| Next quarter | N/A | -3.82 | 1.0 |
| Current year | N/A | -1.91 | 1.0 |
| Next year | N/A | -0.11 | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 10.47 | 15.45 | -31.98 | 6.8 |
| Y/Y | 999 | -36.88 | -29.16 | -20.84 | 3.3 |
| 3y average | 999 | -97.81 | -63.21 | -72.1 | 3.3 |
| 5y average | 999 | -11848.15 | -63.21 | -2259.63 | 3.3 |
| Weighted average score | 4.2 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |